乳腺癌骨转移药物治疗研究进展  

Research progress and prospect of drug therapy for bone metastasis of breast cancer

作　　者：孙展已(综述) 滕旭(审校)[2] Sun Zhanyi;Teng Xu(Xuanwu Hospital,Capital Medical University,Beijing 100037,China)

机构地区：[1]首都医科大学宣武医院,北京100037 [2]首都医科大学基础医学院生物化学与分子生物学系/北京市肿瘤侵袭与转移机制研究重点实验室,北京100069

出　　处：《疑难病杂志》2025年第4期503-507,512,共6页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金资助项目(82273403);首都医科大学长学制导师项目(CXZDS2022036)。

摘　　要：乳腺癌是女性最为常见的恶性肿瘤,其中乳腺癌骨转移是乳腺癌晚期患者中最常见的并发症,严重影响患者的生活质量和总生存期。在目前的临床治疗中,完全治愈依然十分困难,但通过药物治疗可以有效缓解患者的骨痛症状,降低骨折等并发症的发生,是十分重要的治疗手段。文章针对目前临床上使用的乳腺癌骨转移主流药物的治疗效果和不良反应进行综述,重点介绍骨靶向药物、靶向药物递送系统(DDS)和人工智能药物研究的最新临床进展。Breast cancer is the most common cancer in women.Bone metastasis is the most common complication in patients with advanced breast cancer,which seriously affects the quality of life and overall survival of patients.In current clinical treatment,complete cure remains a very difficult issue.However,through medication,the bone pain symptoms of patients can be effectively alleviated,and the occurrence of complications such as fractures can be reduced,making it a crucial treatment method.This article provides a review of the therapeutic effects and side effects of the mainstream drugs currently used in the treatment of breast cancer bone metastasis.It focuses on the latest clinical advancements in bone-targeted drugs,targeted drug delivery systems(DDS)and artificial intelligence in drug research.

关 键 词：乳腺癌 骨转移 药物治疗 靶向药物递送系统 人工智能药物研究 

分 类 号：R737.9[医药卫生—肿瘤]